Clinical Trial Update: Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/Phase 2 trial results for the combination of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) with tislelizumab in advanced solid tumors, with Phase 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Non-small Cell Lung Cancer

Drugs mentioned

• Alcestobart (alcestobart)
• Surzebiclimab (surzebiclimab)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: BeiGene | Conditions: Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in, HNSCC for Phase 2 Dose Expansion | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2026-04-02